BioLife (BLFS) files Form 144 to sell 10,000 vested shares on NASDAQ

Rhea-AI Filing Summary

Form 144 notice for BioLife Solutions, Inc. (BLFS) reports a proposed sale of 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $255,265 and an approximate sale date of 08/25/2025. The shares were acquired on 03/03/2025 as restricted stock that vested under a registered plan and the payment type is recorded as compensation. The filer reports no securities sold in the past three months and includes the required representation that they are not aware of undisclosed material adverse information.

Positive

• Timely regulatory disclosure via Form 144 enables transparent resale of vested restricted shares
• Securities originated from restricted stock vesting under a registered plan, indicating compensation-related liquidity rather than an open-market purchase

Negative

• Insider sale planned of 10,000 shares (aggregate value $255,265) will increase available supply
• No details on the selling person's role or reason beyond compensation are provided in the filing

Insights

Securities Analyst

TL;DR Routine insider sale of newly vested restricted shares, disclosed via Form 144; transaction appears administrative rather than indicative of distress.

The filing shows 10,000 vested restricted shares to be sold through Morgan Stanley Smith Barney with an aggregate value of $255,265. Acquisition occurred on 03/03/2025 as compensation under a registered plan, which typically indicates employee or executive equity vesting being monetized. No prior sales in the past three months are reported, reducing concerns about heavy recent insider disposals. This is a standard Rule 144 notice enabling resale of restricted securities; absent other information in this filing, it is a routine disclosure rather than a material corporate event.

Corporate Governance Specialist

TL;DR Proper compliance with Rule 144 filing for vested compensation; transparency is positive but sale still adds insider supply to market.

The filer documents the nature of acquisition as restricted stock vesting and records compensation as the payment source, which aligns with required disclosures for insiders monetizing vested awards. The planned sale represents a small fraction of the reported outstanding shares (10,000 of 47,905,265 outstanding). The form includes the standard attestation regarding lack of undisclosed material information, and there are no reported sales in the prior three months. From a governance perspective the filing meets regulatory norms and supports market transparency.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10000	255265.00	47905265	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/03/2025	Restricted stock vesting under a registered plan	Issuer			10000	03/03/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BioLife Solutions (BLFS) Form 144 report?

The filing reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $255,265, approximate sale date 08/25/2025.

How were the shares acquired according to the Form 144?

The shares were acquired on 03/03/2025 as restricted stock vesting under a registered plan and are characterized as compensation.

Does the filing show prior insider sales in the last three months for BLFS?

No; the filing states "Nothing to Report" for securities sold during the past three months.

Through which broker and on which exchange will the BLFS shares be sold?

The sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

What representation does the seller make in the Form 144?

The seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.